Mirum Pharmaceuticals Inc (MIRM)
25.82
+0.22
(+0.86%)
USD |
NASDAQ |
May 03, 16:00
25.82
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Enterprise Value: 1.223B for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 1.223B |
| May 01, 2024 | 1.229B |
| April 30, 2024 | 1.200B |
| April 29, 2024 | 1.198B |
| April 26, 2024 | 1.170B |
| April 25, 2024 | 1.171B |
| April 24, 2024 | 1.149B |
| April 23, 2024 | 1.168B |
| April 22, 2024 | 1.156B |
| April 19, 2024 | 1.139B |
| April 18, 2024 | 1.128B |
| April 17, 2024 | 1.141B |
| April 16, 2024 | 1.149B |
| April 15, 2024 | 1.144B |
| April 12, 2024 | 1.175B |
| April 11, 2024 | 1.234B |
| April 10, 2024 | 1.225B |
| April 09, 2024 | 1.252B |
| April 08, 2024 | 1.238B |
| April 05, 2024 | 1.254B |
| April 04, 2024 | 1.211B |
| April 03, 2024 | 1.183B |
| April 02, 2024 | 1.205B |
| April 01, 2024 | 1.216B |
| March 28, 2024 | 1.201B |
| Date | Value |
|---|---|
| March 27, 2024 | 1.201B |
| March 26, 2024 | 1.191B |
| March 25, 2024 | 1.249B |
| March 22, 2024 | 1.248B |
| March 21, 2024 | 1.244B |
| March 20, 2024 | 1.289B |
| March 19, 2024 | 1.290B |
| March 18, 2024 | 1.241B |
| March 15, 2024 | 1.278B |
| March 14, 2024 | 1.344B |
| March 13, 2024 | 1.325B |
| March 12, 2024 | 1.312B |
| March 11, 2024 | 1.286B |
| March 08, 2024 | 1.343B |
| March 07, 2024 | 1.338B |
| March 06, 2024 | 1.347B |
| March 05, 2024 | 1.328B |
| March 04, 2024 | 1.360B |
| March 01, 2024 | 1.388B |
| February 29, 2024 | 1.362B |
| February 28, 2024 | 1.370B |
| February 27, 2024 | 1.404B |
| February 26, 2024 | 1.378B |
| February 23, 2024 | 1.319B |
| February 22, 2024 | 1.339B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
30.99M
Minimum
Nov 20 2019
1.628B
Maximum
Dec 15 2023
574.10M
Average
424.88M
Median
Enterprise Value Benchmarks
| Vanda Pharmaceuticals Inc | -118.99M |
| Sarepta Therapeutics Inc | 12.19B |
| Puma Biotechnology Inc | 241.86M |
| Reneo Pharmaceuticals Inc | -45.14M |
| Tharimmune Inc | -6.504M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.66M |
| Revenue (Quarterly) | 69.55M |
| Total Expenses (Quarterly) | 102.14M |
| EPS Diluted (Quarterly) | -0.7095 |
| Gross Profit Margin (Quarterly) | 64.03% |
| Profit Margin (Quarterly) | -51.27% |
| Earnings Yield | -15.57% |
| Normalized Earnings Yield | -15.57 |